Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: A single centre experience

Neoplasma

Volumn 55, Issue 5, 2008, Pages 428-436

  Ballova, V ^a   Ladicka, M ^a   Vranovsky, A ^a   Lakota, J ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Autologus transplantation; High dose chemotherapy; Hodgkin's lymphoma

Indexed keywords

ACICLOVIR; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; LACTATE DEHYDROGENASE; LOMUSTINE; MELPHALAN; METHOTREXATE; OFLOXACIN; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; AUTOTRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SALVAGE THERAPY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SURVIVAL;

ADOLESCENT; ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 53449096768     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. LINCH DC, WINFIELD D, GOLDSTONE AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
2. SCHMITZ N, PFISTNER B, SEXTRO M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
3. SCHMITZ N, LINCH DC, DREGER P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357. (Pubitemid 26046102)
4. MAJOLINO I, PEARCE R, TAGHIPOUR G et al. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow transplantation Registry data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509-517.
5. BRUGGER W, BROSS KJ, GLATT M et al. Mobilisation of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
6. KVALHEIM G, ERIKSTEIN B, GILEN E et al. The presence of micrometastases in bone marrow and blood in in high-risk stage II breast cancer patients before and after high-dose therapy. Autologous Blood and Marrow transplantation. Proceedings of the Ninth International Symposium, Arlington, Texas. Carden Jennings Publishing: Charlottesville, VA, 1999, pp 247-255.
7. WOLF J, KAPP U, BOHLEN H et al. Peripheral blood mononuclear cells of patients with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996; 87: 3418-3428
8. SCHILLER G, VESCIO R, FREYTES C et al. Transplantation of CD 34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-397.
9. MAMPARA MY,KORNER IJ, HILDEBRANDT M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34+ cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997; 89: 337-344.
10. BLYSTARD AK, HOLTE H, KVALOY et al.High-dose therapy in patients with Hodgkin's disease: the use of selected CD34+ cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant 2001; 3: 295-305.
11. HORNING SJ, CHAO NJ, NEGRIN RS et al. High dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent and refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
12. SUREDA A, ARRANZ R, IRIONDO A et al. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 Patients from Grupo Aspanol de Linfomas/Transplantate Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2002; 19: 1395-1404.
13. LAVOIE JC, CONNORS JM, PHILLIPS GL et al. High dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: lon-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473-1478.
14. FERMÉ C, MOUNIER N, DIVINE M et al.Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial. J Clin Oncol 2002; 20: 467-475.
15. MOSKOWITZ CH, NIMER SD, ZELENETZ AD et al. A 2-step comprehensive high-dose chmoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
16. JOSTING A, RUDOLPH C, MAPARA M et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116-123. (Pubitemid 40124488)
17. REECE DE, CONNORS JM, SPINELLI JJ et al. High-dose therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83:1193-1199.
18. ANDRÉ M, HENRY-AMAR M, PICO JL et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. J Clin Oncol 1999; 17: 222-229. (Pubitemid 29022397)
19. SWEETENHAM JW, CARELLA AM, TAGHIPOUR G et al. High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17: 3101-3109.
20. JABBOUR E, HOSING CH, AYERS G et al. Pretransplant positive positron emission tomography/ gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109: 2481-2489.
21. TARELLA C, CUTTICA A, VITOLO U et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. Cancer 2003; 97: 2748-2759.
22. CARELLA AM, CAVALIERE M, LERMA E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogenic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistent Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
23. BLYSTAD AK, TORLAKOVIC E, HOLTE H et al. CD34+ cell enrichment depletes atypical CD30+ cells from PBSC grafts in patients with HD. Cytotherapy 2001; 3: 295-305.
24. LAKOTA J. Use of selected CD34+ cells in the treatment of relapsed Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24: 697-699.
25. LAKOTA J, BALLOVA V, DRGONA et al. Use od selected CD34+ cells in the treatment of relapsed/progressive HD: experience from a single center. Cytotherapy 2002; 4: 177-180.
26. SORA F, FEBO AL, PRICCIRILLO N et al. Autologous stem cell transplantation for primary refractory or relapsing Hodgkin's disease: comparison between CD34+ immunoselected and unselected cell graft. Gene Ther Mol Biol 2007; 11: 21-26.